CRVO is the second most common retinal vascular disorder after diabetic retinopathy, caused by obstruction of the central retinal vein at or posterior to the optic nerve head, resulting in acute, painless, unilateral vision loss. [1-2] It is classified as ischemic or non-ischemic, which fundamentally determines prognosis and complication risk. [2-3]
1. History
- Onset and character: Sudden, painless, unilateral decrease in vision — often noticed upon waking or when the unaffected eye is inadvertently covered [2][4]
- Severity: Range from mild blurring to profound vision loss; ischemic CRVO typically presents with VA worse than 20/200 [3-4]
- Timing: Some patients are unaware of unilateral loss and present late, sometimes only after developing complications (e.g., neovascular glaucoma causing eye pain) [2]
- Associated symptoms: Reduced depth perception, visual field defects, floaters (if vitreous hemorrhage)
- Important negatives: No pain at onset (pain suggests neovascular glaucoma or alternative diagnosis), no photopsias or curtain-like visual field loss (suggests retinal detachment)
2. Alarm Features
- Relative afferent pupillary defect (RAPD) — correlates with degree of ischemia and risk of neovascularization [1][5]
- VA worse than 20/200 at presentation — suggests ischemic CRVO with high risk of neovascular glaucoma [2][4]
- Iris or angle neovascularization (rubeosis iridis) — precursor to neovascular glaucoma; ~25% of CRVO patients develop iris neovascularization [1]
- Eye pain developing after initial painless vision loss — suggests neovascular glaucoma [2]
- Bilateral CRVO — raises concern for systemic hypercoagulable state, hyperviscosity syndrome, or multiple myeloma [2]
- Age <40 years — warrants expanded workup for thrombophilia [1-2]
3. Medications
- First-line treatment: Intravitreal anti-VEGF agents — FDA-approved options include ranibizumab, aflibercept (2 mg), and faricimab-svoa; bevacizumab is used off-label with demonstrated efficacy [1-2]
- Second-line: Intravitreal corticosteroids (dexamethasone implant, triamcinolone) — effective but associated with secondary glaucoma and cataract formation [1-2]
- Panretinal photocoagulation (PRP): Indicated for CRVO with iris or retinal neovascularization [1]
- Medications to review: Oral contraceptives, hormone replacement therapy, and any medications contributing to hypercoagulability
- No role for systemic anticoagulation in routine CRVO management; aspirin may be considered for overall cardiovascular risk reduction [6]
4. Diet
- No specific dietary triggers for CRVO
- Long-term dietary management focuses on cardiovascular risk reduction: DASH or Mediterranean-style diet to control hypertension, diabetes, and dyslipidemia — all modifiable risk factors [1]
- Adequate hydration to avoid hemoconcentration
5. Review of Systems
- Cardiovascular: Chest pain, dyspnea, palpitations, claudication — RVO patients have increased risk of stroke (RR 1.45), MI (RR 1.26), and heart failure (RR 1.53) [7]
- Neurologic: Headache, focal deficits, transient ischemic symptoms
- Hematologic: Easy bruising, prior DVT/PE, recurrent pregnancy loss (suggests antiphospholipid syndrome)
- Endocrine: Polyuria, polydipsia (undiagnosed diabetes)
- Rheumatologic: Joint pain, rash, oral ulcers (SLE — 3.5× higher CRVO incidence) [1]
- Sleep: Snoring, daytime somnolence (obstructive sleep apnea is a risk factor) [1]
6. Collateral History and Family History
- Family history of thrombophilia, DVT/PE, or early cardiovascular disease
- Family history of glaucoma (major ocular risk factor for CRVO) [4]
- Social history: Smoking status, alcohol use
- Prior episodes of vision loss in either eye (1% per year risk of fellow-eye CRVO) [1]
7. Risk Factors
- Systemic: Hypertension (strongest), diabetes mellitus, dyslipidemia, atherosclerosis, obesity [1][4]
- Ocular: Glaucoma or elevated intraocular pressure (compromises venous outflow through lamina cribrosa) [2][4]
- Hematologic: Hyperhomocysteinemia, anticardiolipin antibodies (most consistently associated thrombophilias) [4]
- Other: Older age, carotid occlusive disease, obstructive sleep apnea, SLE, depression [1]
- Young patients (<50): 58% have a nontraditional risk factor identified on systemic evaluation [1]
8. Differential Diagnosis
- Central retinal artery occlusion (CRAO): Painless vision loss but fundus shows pale retina with cherry-red spot, not hemorrhages
- Diabetic retinopathy: Bilateral, gradual; hemorrhages in all quadrants but with microaneurysms and neovascularization pattern
- Papilledema: Bilateral disc edema, normal VA initially, associated with headache/elevated ICP
- Ocular ischemic syndrome (carotid occlusive disease): Dilated veins but typically low-pressure retinopathy with dot-blot hemorrhages in midperiphery
- Hypertensive retinopathy: Bilateral, flame hemorrhages, cotton-wool spots, AV nicking
- Papillophlebitis: CRVO variant in young patients (20–40 years) with prominent disc swelling; generally good prognosis but ~20% have substantial vision loss [2]
- Anterior ischemic optic neuropathy: Disc edema with altitudinal field defect, no diffuse retinal hemorrhages
9. Past Medical History
- Hypertension, diabetes, hyperlipidemia — most common associated comorbidities [2]
- Glaucoma — strong independent risk factor for CRVO [4]
- Prior RVO in either eye
- History of DVT/PE, stroke, MI, or other thrombotic events
- Autoimmune conditions (SLE, antiphospholipid syndrome)
- Prior ocular surgery or trauma
10. Physical Exam
- Visual acuity: Ranges from mild reduction to counting fingers; VA <20/200 suggests ischemic type [3-4]
- Pupillary exam: RAPD — key finding correlating with ischemia severity and neovascularization risk [1][5]
- Slit-lamp biomicroscopy: Examine iris carefully for fine new vessels (rubeosis iridis) [1]
- IOP measurement: Elevated IOP may indicate pre-existing glaucoma or neovascular glaucoma
- Gonioscopy: Perform prior to dilation, especially in ischemic CRVO, to assess for angle neovascularization [1]
- Dilated fundoscopy: Classic "blood and thunder" appearance — intraretinal hemorrhages in all four quadrants, dilated and tortuous veins, cotton-wool spots, disc edema [2][4][8]
- Blood pressure: Often elevated; should be measured in all patients
- Cardiovascular exam: Carotid bruits, irregular rhythm, signs of heart failure
11. Lab Studies
Routine for all CRVO patients: [4][9]
- CBC with differential
- Fasting glucose / HbA1c
- Lipid panel
- Blood pressure measurement
- BMP/CMP (renal function)
Selective — patients <50 years, bilateral RVO, or no traditional risk factors: [1-2][9]
- Homocysteine level
- Antiphospholipid antibodies / anticardiolipin antibodies
- Lupus anticoagulant
- Protein C, Protein S, Antithrombin III activity
- Factor V Leiden, Prothrombin G20210A mutation
- Serum protein electrophoresis (to rule out multiple myeloma / hyperviscosity) [2]
Monitoring: ESR/CRP if vasculitis suspected; ANA if SLE suspected
A meta-analysis found that prevalences of inherited thrombophilias in RVO patients were similar to healthy subjects, suggesting routine thrombophilia screening is not supported in typical older patients with traditional risk factors. [10]
12. Imaging
- Optical coherence tomography (OCT): First-line to quantify macular edema and monitor treatment response [4]
- Fundus fluorescein angiography (FFA): Assesses perfusion status and degree of ischemia; ≥10 disc areas of non-perfusion defines ischemic CRVO [2][4]
- Wide-field fundus photography: Documents extent of hemorrhages and disease severity [2]
- OCT angiography (OCTA): Noninvasive assessment of macular vascular density and foveal avascular zone [11]
- Carotid Doppler ultrasound: Consider to evaluate for carotid occlusive disease [1][12]
- Echocardiography: Consider in patients with multiple cardiovascular risk factors [12]
13. Special Tests
- Ischemic vs. non-ischemic classification: Based on VA (<20/200), RAPD, extent of hemorrhages, cotton-wool spots, and FFA non-perfusion [2]
- Gonioscopy: Essential to detect angle neovascularization before it causes neovascular glaucoma [1]
- Visual field testing (Goldmann perimetry): Assesses functional impact; severe defects correlate with ischemic type [3]
- 7-day Holter ECG: One study found AF prevalence of 18.4% in RVO patients after prolonged monitoring (vs. 10.2% on initial assessment), supporting prolonged ECG monitoring [13]
14. ECG
- 12-lead ECG should be obtained as part of cardiovascular risk assessment
- Screen for atrial fibrillation — prevalence ~10–18% in RVO patients [13]
- Consider prolonged Holter monitoring — AF detection rate nearly doubled with 7-day monitoring compared to baseline ECG [13]
- RVO is associated with increased risk of stroke (RR 1.45) and MI (RR 1.26), making cardiac evaluation clinically important [7]
15. Assessment
Severity stratification — the critical distinction is ischemic vs. non-ischemic: [2-3]
Complications: Macular edema (most common cause of vision loss), neovascular glaucoma (most feared), vitreous hemorrhage, epiretinal membrane, traction retinal detachment. [1-2]
16. Treatment Plan
Initial stabilization (ED/urgent care)
- No acute ED intervention changes visual outcome; the priority is urgent ophthalmology referral (within 24–48 hours) [5]
- Control blood pressure if acutely elevated
- In wilderness/remote settings: topical prednisolone 1% (2 drops QID) may be started pending evacuation [5]
Definitive ophthalmologic treatment
- Anti-VEGF intravitreal injections — first-line for macular edema. Monthly injections for initial 6 months, then treat-and-extend or PRN: [1-2]
- Aflibercept 2 mg, ranibizumab 0.5 mg, faricimab 6 mg (FDA-approved)
- Bevacizumab 1.25 mg (off-label, much less expensive; non-inferior to aflibercept at 6 months per SCORE2) [1-2]
- Mean improvement: 15+ ETDRS letters with anti-VEGF vs. minimal gain with observation [1][16]
- Intravitreal corticosteroids (second-line): Dexamethasone implant (Ozurdex) or triamcinolone — for patients with suboptimal anti-VEGF response or contraindications [1-2]
- Panretinal photocoagulation: For ischemic CRVO with iris or retinal neovascularization [1]
- Systemic risk factor management: Optimize BP, glucose, lipids in partnership with PCP [1]
Important: Delay in initiating anti-VEGF treatment results in worse visual outcomes. [1] Approximately 56–75% of CRVO patients still require ongoing injections at 5+ years. [2]
17. Disposition
- Discharge from ED with urgent ophthalmology referral within 24–48 hours — CRVO does not require hospital admission unless complicated by neovascular glaucoma with uncontrolled IOP or significant systemic comorbidity
- Admission criteria: Neovascular glaucoma with acutely elevated IOP unresponsive to medical therapy; concurrent acute systemic event (stroke, MI)
- Specialist consultation triggers:
- Ophthalmology/retina specialist — all cases
- Internal medicine/PCP — cardiovascular risk factor assessment and management [1]
- Hematology — patients <50 years, bilateral RVO, or recurrent RVO for hypercoagulable workup [1]
18. Follow Up / Return Precautions
- Ophthalmology follow-up: Within 1–2 days for initial evaluation; then monthly during anti-VEGF loading phase; ongoing monitoring for neovascularization (especially first 4 months — highest conversion risk from non-ischemic to ischemic) [2][14]
- PCP follow-up: Within 1–2 weeks for cardiovascular risk factor optimization [1]
- Return precautions — seek immediate care for:
- New eye pain or redness (neovascular glaucoma)
- Sudden worsening of vision in either eye
- New floaters or flashing lights
- Symptoms of stroke (facial droop, weakness, speech difficulty) or MI (chest pain, dyspnea)
- Patient counseling: CRVO should be considered end-organ damage from cardiovascular disease; aggressive risk factor modification reduces future cardiovascular events and fellow-eye RVO risk (1% per year) [1][4]
- Expected course: Non-ischemic CRVO has favorable prognosis with treatment (83% achieve VA ≥20/100); ischemic CRVO carries poor visual prognosis (only 12% achieve VA ≥20/100) despite treatment [3]
Images
References
1. Retinal Vein Occlusions Preferred Practice Pattern®. — Kovach JL, Bailey ST, Kim SJ, et al. Ophthalmology. 2025.
2. Retinal Vascular Occlusions. — Scott IU, Campochiaro PA, Newman NJ, Biousse V. Lancet. 2020.
3. Natural History of Visual Outcome in Central Retinal Vein Occlusion. — Hayreh SS, Podhajsky PA, Zimmerman MB. Ophthalmology. 2011.
4. Retinal-Vein Occlusion. — Wong TY, Scott IU. The New England Journal of Medicine. 2010.
5. Wilderness Medical Society Clinical Practice Guidelines for Treatment of Eye Injuries and Illnesses in the Wilderness: 2024 Update. — Paterson R, Drake B, Tabin G, Cushing T. Wilderness & Environmental Medicine. 2024.
6. The Role of Coagulation Disorders in Patients With Retinal Vein Occlusion. — Napal JJ, Neila S, Pérez-Montes R, et al. QJM : Monthly Journal of the Association of Physicians. 2016.
7. ASSOCIATION OF RETINAL VEIN OCCLUSION WITH CARDIOVASCULAR EVENTS AND MORTALITY: A Systematic Review and Meta-Analysis. — Wu CY, Riangwiwat T, Limpruttidham N, et al. Retina. 2019.
8. Intravitreal Steroids Versus Observation for Macular Edema Secondary to Central Retinal Vein Occlusion. — Gewaily D, Muthuswamy K, Greenberg PB. The Cochrane Database of Systematic Reviews. 2015.
9. Laboratory Evaluation of Hypercoagulable States in Patients With Central Retinal Vein Occlusion Who Are Less Than 56 Years of Age. — Lahey JM, Tunç M, Kearney J, et al. Ophthalmology. 2002.
10. Inherited and Acquired Thrombophilia in Adults With Retinal Vascular Occlusion: A Systematic Review and Meta-Analysis. — Romiti GF, Corica B, Borgi M, et al. Journal of Thrombosis and Haemostasis : JTH. 2020.
11. Evaluation of Cardiovascular Risk Scores and Their Association With Vascular Structural Changes in Patients With Retinal Vein Occlusion. — Kıvrak U, Unkun T. Angiology. 2025.
12. Cardiovascular Risk Factors in Patients With Combined Central Retinal Vein Occlusion and Cilioretinal Artery Occlusion: Case Report. — Grzybowski A, Elikowski W, Gaca-Wysocka M. Medicine. 2018.
13. Atrial Fibrillation in Retinal Vascular Occlusion Disease and Non-Arteritic Anterior Ischemic Optic Neuropathy. — Callizo J, Feltgen N, Ammermann A, et al. PloS One. 2017.
14. Anti-Vascular Endothelial Growth Factor for Macular Oedema Secondary to Central Retinal Vein Occlusion. — Braithwaite T, Nanji AA, Lindsley K, Greenberg PB. The Cochrane Database of Systematic Reviews. 2014.
15. Natural History of Central Retinal Vein Occlusion: An Evidence-Based Systematic Review. — McIntosh RL, Rogers SL, Lim L, et al. Ophthalmology. 2010.
16. Effectiveness and Safety of Anti-Vascular Endothelial Growth Factor Therapies for Macular Edema in Retinal Vein Occlusion: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. — Chen KY, Chan HC, Chan CM. Survey of Ophthalmology. 2025.